Talazoparib and Avelumab for Mismatch Repair Proficient Endometrial Cancer
16483
post-template-default,single,single-post,postid-16483,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Talazoparib and Avelumab for Mismatch Repair Proficient Endometrial Cancer

Home > Blogs  > Talazoparib and Avelumab for Mismatch Repair Proficient Endometrial Cancer

13 Aug Talazoparib and Avelumab for Mismatch Repair Proficient Endometrial Cancer

Posted at 09:49h in Blogs by

In patients with recurrent mismatch repair proficient (MMRP) Endometrial Cancer, treatment with talazoparib and avelumab showed 11.4 % confirmed ORR and 22.9 % PFS at 6 months. Patients with homologous recombination repair (HRR) alterations and/or a platinum-free interval (PFI) of ≥6 months were more likely to derive clinical benefit compared with non–HRR-altered tumors and/or PFI ≤6 months and exhibited better PFS.                          (Ref: Konstantinopoulos PA et al. JAMA Oncol. July 28, 2022.)

#oncologyresearch #clinicaldevelopment #cancerresearch

https://www.linkedin.com/feed/update/urn:li:activity:6964212547470155777

No Comments

Sorry, the comment form is closed at this time.